Background: Dipeptidyl peptidase-4 (DPP-4) is an aminopeptidase that inhibits the enzymatic degradation of glucagon-like peptide-1, glucose-dependent insulinotropic polypeptides, neuropeptides, and various chemokines. Recent studies reported that serum DPP-4 concentration is correlated with clinical parameters of obesity. However, research on these correlations has never been conducted in Korea. Therefore, we investigated the relationship between serum DPP-4 concentration and various clinical parameters of obesity in the Korean population. Methods: Patients who visited the Health Promotion Center at Keimyung University Dongsan Medical Center for a regular medical examination between January 2013 and March 2013 and consented to participate in this study were included. We measured and analyzed parameters of obesity. In addition, serum DPP-4 concentration was determined using an enzyme-linked immunosorbent assay kit. Results: Serum DPP-4 concentration was positively correlated with lean body mass, total cholesterol level, and creatinine level. Serum DPP-4 concentration was higher in the obese group than in the normal body mass index (BMI) group. No significant difference in serum DPP-4 concentration was found between the metabolically healthy group and metabolically unhealthy group. Conclusion: Serum DPP-4 concentration was higher in the obesity group than in the normal BMI group, which was associated with obesity-related factors.
INTRODUCTION
Obesity, one of the typical characteristics of metabolic syndrome, is recognized as a major health problem and is associated with insulin resistance, diabetes, atherosclerosis, hypertension, chronic renal insufficiency, and cardiovascular diseases worldwide. 1 The World Health Organization (WHO) has reported that there are more than 600 million obese adults worldwide 2 , and the National Health and Nutrition Examination Survey (2010) conducted in the United States has reported that people aged 20 years or older account for 35.7% of the entire obese population with body mass index (BMI) greater than or equal to 30 kg/m pokines released by adipose cells such as leptin and adiponectin regulate lipid metabolism, energy homeostasis, and insulin resistance; thereby, affecting the development of metabolic syndrome associated with obesity. 5, 6 By understanding the changes in adipokine levels, metabolic dysregulation may be predicted, and a considerable amount of research has been conducted in this regard.
Dipeptidyl peptidase-4 (DPP-4), a serine protease, degrades peptides containing alanine or proline residues and amino-terminal residues of proteins. 7 DPP-4 is an aminopeptidase found in most tissues of the body, including the liver, lung, kidney, intestine, lymph nodes, and endothelial cells, and resides on cell membranes where it exerts its effect. Physiological effects of DPP-4 can be broadly divided into enzymatic effects and non-enzymatic effects.
A major example of the enzymatic effects of DPP-4 is the inhibition of incretins such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide. Therefore, inhibiting DPP-4 activates incretin effects, and lowers blood glucose levels. For this reason, DPP-4 inhibitors have been widely used as antihyperglycemic drugs. 8, 9 Non-enzymatic effects of DPP-4 are reported to be associated with immune regulation, behavioral response, and inflammation depending on the substance on which DPP-4 acts. 10 In previous studies, DPP-4 activity was associated with obesity, diabetes, and fatty liver, serum DPP-4 concentration increased as the size of adipose cells increased, and serum DPP-4 concentration was higher in obese people than in underweight people. [11] [12] [13] [14] Based on all these results, serum DPP-4 is considered a new obesity-related factor. However, there has not been any research on the correlation between DPP-4 concentration and obesity in the Korean population. The goals of this study were to measure the serum DPP-4 concentration in Korean participants undergoing routine medical examination and to investigate the association of serum DPP-4 concentration with obesity-related factors, including adiponectin. was log-transformed because the data were not normally distributed. A multiple regression analysis was performed to identify factors that are independently associated with serum DPP-4 concentration.
METHODS

Participants and methods
The 95% confidence interval was estimated based on a binomial distribution. The level of statistical significance was set at a P< 0.05.
RESULTS
General characteristics of the participants
The mean age of all participants was 42.58 ± 9.70 years. The participants consisted of 188 men (41.6%), and 264 women (58.4%).
The mean BMI was 23.15 ± 3.12 kg/m 2 , the mean body fat percentage was 27.95% ± 6.18%, the mean systolic pressure was 118.68 ± 14.21 mmHg, the mean diastolic pressure was 74.00 ± 9.86 mmHg, the mean total cholesterol level was 188.41 ± 33.27 mg/dL, the mean triglyceride level was 103.96 ± 74.60 mg/dL, the mean HDL level was 52.35 ± 10.90 mg/dL, the mean low-density lipoprotein (LDL) level was 156.85 ± 42.17 mg/dL, the mean fasting glucose level was 84.95 ± 12.74 mg/dL, the mean insulin level was 4.10 ± 2.64 µIU/mL, the mean HOMA-IR was 0.90 ± 0.80, and the mean serum log DPP-4 concentration was 2.69 ± 0.11 ng/ mL. The mean adiponectin level was 5.64 ± 4.06 µg/mL, and the mean leptin level was 2.08 ± 1.71 ng/mL. Fatty liver was observed in 111 subjects (24.6%) ( Table 1) .
Correlation between serum DPP-4 concentration and obesity-related factors in all groups
We analyzed the correlations between serum DPP-4 concentration and obesity-related factors in all groups. Serum DPP-4 concentration was significantly positively correlated with body weight, BMI, lean body mass, waist circumference, hip circumference, waist-to-hip ratio (WHR), blood pressure, total cholesterol, triglyceride, LDL, blood urea nitrogen (BUN), and creatinine, and significantly negatively correlated with body fat percentage and adiponectin ( found to be significantly associated with serum DPP-4 concentration in the correlation analysis) showed that serum DPP-4 concentration was significantly positively correlated with lean body mass, total cholesterol, and creatinine (Table 3) .
Comparison of serum DPP-4 concentration by BMI and obesity type
Since a correlation was found between serum DPP-4 concentra- However, no significant difference in serum log DPP-4 concentration was found between the MHO and MUHO groups (2.71 ± 0.11, and 2.72 ± 0.09, respectively) (P = 0.592). Thus, no significant difference in serum DPP-4 concentration was found according to obesity type (Table 5) .
DISCUSSION
In this study, serum DPP-4 concentration was found to be positively correlated with lean body mass, total cholesterol, and creatinine. Serum DPP-4 concentration was also elevated in the obese group compared to the normal weight group. been reported that symptoms of metabolic syndrome differ depending on fat distribution. 24, 25 Glutofemoral fat is known to play a protective role that contributes to healthy metabolism unlike abdominal fat. 24, 25 However, it is not possible to determine whether the body fat percentage reduction signifies a reduction in the amount of gynoid fat as was the case in a study by Neidert et al.
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, and a further investigation is needed in this regard. DPP-4 is expressed in various tissues, and its role as a myokine has been suggested after the discovery that myotubes release DPP-4. 26, 27 While the secretion of DPP-4 by muscles was found to increase due to the effects of whey proteins and muscle contraction in cell and animal experiments, the same was not observed in human experiments. 27 Little has been reported about the association between DPP-4 and muscle in clinical research. In the multivariate analysis performed in this study, an association between DPP-4 and muscle was consistently observed, and thus, additional research on the role of DPP-4 in muscle is necessary. In addition, different results can be observed within an obese population according to obesity phenotype. Numerous studies have recently reported that obesity can be further classified into metabolically health obesity, metabolically unhealthy obesity, and so on depending on fat distribution. 28, 29 In a study by Turker et al. 29 , blood pressure, BMI, triglyceride, LDL, and fasting glucose levels, and HOMA-IR were higher in the MUHO group than in the MHO group. They reported that while the risk for cardiovascular diseases in the MHO group was not as high as that in the MUHO group, it was higher than that in the normal weight group. 29 In this study, similar results regarding metabolic factors were observed, and the proportion of patients with fatty liver was higher in the MUHO group than in the MHO group. However, while a significant difference in DPP-4 concentration was found between the normal weight and obese groups, no significant difference was found between the MHO and MUHO groups. Since the MUHO group had a relatively small number of subjects compared to the MHO group, further investigation involving a greater number of patients is needed.
Obesity is a risk factor for renal and cardiovascular diseases. 30, 31 Recent studies have reported an association of DPP-4 in blood with cardiac diseases and kidney damage that may or may not be related to GLP-1. Inhibition of DPP-4 has been reported to have cardio-protective and renal-protective effects. 32, 33 In the present study, a positive correlation was found between serum DPP-4 concentration and creatinine levels. This finding may be associated with the reports that inhibition of DPP-4 inhibits kidney damage.
In summary, serum DPP-4 concentration was significantly higher among Korean participants who were obese than those of normal weight and associated with various obesity-related factors.
However, since this study only included patients from a single institution, a large-scale research study must be conducted in the future. 
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